Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 73
Filtrar
Más filtros

Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
BMC Med ; 21(1): 269, 2023 07 24.
Artículo en Inglés | MEDLINE | ID: mdl-37488589

RESUMEN

BACKGROUND: Chronic disease management (CDM) through sustained knowledge translation (KT) interventions ensures long-term, high-quality care. We assessed implementation of KT interventions for supporting CDM and their efficacy when sustained in older adults. METHODS: Design: Systematic review with meta-analysis engaging 17 knowledge users using integrated KT. ELIGIBILITY CRITERIA: Randomized controlled trials (RCTs) including adults (> 65 years old) with chronic disease(s), their caregivers, health and/or policy-decision makers receiving a KT intervention to carry out a CDM intervention for at least 12 months (versus other KT interventions or usual care). INFORMATION SOURCES: We searched MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials from each database's inception to March 2020. OUTCOME MEASURES: Sustainability, fidelity, adherence of KT interventions for CDM practice, quality of life (QOL) and quality of care (QOC). Data extraction, risk of bias (ROB) assessment: We screened, abstracted and appraised articles (Effective Practice and Organisation of Care ROB tool) independently and in duplicate. DATA SYNTHESIS: We performed both random-effects and fixed-effect meta-analyses and estimated mean differences (MDs) for continuous and odds ratios (ORs) for dichotomous data. RESULTS: We included 158 RCTs (973,074 participants [961,745 patients, 5540 caregivers, 5789 providers]) and 39 companion reports comprising 329 KT interventions, involving patients (43.2%), healthcare providers (20.7%) or both (10.9%). We identified 16 studies described as assessing sustainability in 8.1% interventions, 67 studies as assessing adherence in 35.6% interventions and 20 studies as assessing fidelity in 8.7% of the interventions. Most meta-analyses suggested that KT interventions improved QOL, but imprecisely (36 item Short-Form mental [SF-36 mental]: MD 1.11, 95% confidence interval [CI] [- 1.25, 3.47], 14 RCTs, 5876 participants, I2 = 96%; European QOL-5 dimensions: MD 0.01, 95% CI [- 0.01, 0.02], 15 RCTs, 6628 participants, I2 = 25%; St George's Respiratory Questionnaire: MD - 2.12, 95% CI [- 3.72, - 0.51] 44 12 RCTs, 2893 participants, I2 = 44%). KT interventions improved QOC (OR 1.55, 95% CI [1.29, 1.85], 12 RCTS, 5271 participants, I2 = 21%). CONCLUSIONS: KT intervention sustainability was infrequently defined and assessed. Sustained KT interventions have the potential to improve QOL and QOC in older adults with CDM. However, their overall efficacy remains uncertain and it varies by effect modifiers, including intervention type, chronic disease number, comorbidities, and participant age. SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD42018084810.


Asunto(s)
Personal de Salud , Ciencia Traslacional Biomédica , Humanos , Anciano , Enfermedad Crónica , Conocimiento , Manejo de la Enfermedad
2.
Harm Reduct J ; 20(1): 60, 2023 04 28.
Artículo en Inglés | MEDLINE | ID: mdl-37118805

RESUMEN

BACKGROUND: Preliminary evidence suggests that people who inject drugs (PWID) may be at an increased risk of developing infective endocarditis (IE), hepatitis C virus (HCV) infection, and/or human immunodeficiency virus (HIV) infection from hydromorphone controlled-release formulation. The hypothesized mechanism is related to insolubility of the drug, which promotes reuse, leading to contamination of injecting equipment. However, this relationship has not been confirmed. We aimed to conduct a systematic review including adult PWID exposed to controlled-release hydromorphone and the risk of acquiring IE, HCV, and HIV. METHODS: We searched MEDLINE, EMBASE, and Evidence Based Medicine reviews from inception until September 2021. Following pilot testing, two reviewers conducted all screening of citations and full-text articles, as well as abstracted data, and appraised risk of bias using the Newcastle-Ottawa scale and Effective Practice and Organization of Care tool. Equity issues were examined using the PROGRESS-PLUS framework. Discrepancies were resolved consistently by a third reviewer. Meta-analysis was not feasible due to heterogeneity across the studies. RESULTS: After screening 3,231 citations from electronic databases, 722 citations from unpublished sources/reference scanning, and 626 full-text articles, five studies were included. Five were cohort studies, and one was a case-control study. The risk of bias varied across the studies. Two studies reported on gender, as well as other PROGRESS-PLUS criteria (race, housing, and employment). Three studies focused specifically on the controlled-release formulation of hydromorphone, whereas two studies focused on all formulations of hydromorphone. One retrospective cohort study found an association between controlled-release hydromorphone and IE, whereas a case-control study found no evidence of an association. One retrospective cohort study found an association between the number of hydromorphone controlled-release prescriptions and prevalence of HCV. None of the studies specifically reported on associations with HIV. DISCUSSION: Very few studies have examined the risk of IE, HCV, and HIV infection after exposure to controlled-release hydromorphone. Very low-quality and scant evidence suggests uncertainty around the risks of blood-borne infections, such as HCV and IE to PWID using this medication.


Asunto(s)
Endocarditis Bacteriana , Endocarditis , Infecciones por VIH , Hepatitis C , Abuso de Sustancias por Vía Intravenosa , Humanos , Adulto , Hidromorfona/efectos adversos , Infecciones por VIH/complicaciones , Abuso de Sustancias por Vía Intravenosa/epidemiología , Preparaciones de Acción Retardada/uso terapéutico , Estudios Retrospectivos , Estudios de Casos y Controles , Hepatitis C/complicaciones , Hepacivirus
3.
J Gen Intern Med ; 36(8): 2414-2426, 2021 08.
Artículo en Inglés | MEDLINE | ID: mdl-33742305

RESUMEN

BACKGROUND: Increasing availability of competing biosimilar alternatives makes it challenging to make treatment decisions. The purpose of this review is to evaluate the comparative efficacy and safety of ultra-long-/long-/intermediate-acting insulin products and biosimilar insulin compared to human/animal insulin in adults with type 1 diabetes mellitus (T1DM). METHODS: MEDLINE, EMBASE, CENTRAL, and grey literature were searched from inception to March 27, 2019. Randomized controlled trials (RCTs), quasi-experimental studies, and cohort studies of adults with T1DM receiving ultra-long-/long-/intermediate-acting insulin, compared to each other, as well as biosimilar insulin compared to human/animal insulin were eligible for inclusion. Two reviewers independently screened studies, abstracted data, and appraised risk-of-bias. Pairwise meta-analyses and network meta-analyses (NMA) were conducted. Summary effect measures were mean differences (MD) and odds ratios (OR). RESULTS: We included 65 unique studies examining 14,200 patients with T1DM. Both ultra-long-acting and long-acting insulin were superior to intermediate-acting insulin in reducing A1c, FPG, weight gain, and the incidence of major, serious, or nocturnal hypoglycemia. For fasting blood glucose, long-acting once a day (od) was superior to long-acting twice a day (bid) (MD - 0.44, 95% CI: - 0.81 to - 0.06) and ultra-long-acting od was superior to long-acting bid (MD - 0.73, 95% CI - 1.36 to - 0.11). For weight change, long-acting od was inferior to long-acting bid (MD 0.58, 95% CI: 0.05 to 1.10) and long-acting bid was superior to long-action biosimilar od (MD - 0.90, 95% CI: - 1.67 to - 0.12). CONCLUSIONS: Our results can be used to tailor insulin treatment according to the desired results of patients and clinicians and inform strategies to establish a competitive clinical market, address systemic barriers, expand the pool of potential suppliers, and favor insulin price reduction. PROSPERO REGISTRATION: CRD42017077051.


Asunto(s)
Biosimilares Farmacéuticos , Diabetes Mellitus Tipo 1 , Biosimilares Farmacéuticos/efectos adversos , Diabetes Mellitus Tipo 1/tratamiento farmacológico , Diabetes Mellitus Tipo 1/epidemiología , Hemoglobina Glucada/análisis , Humanos , Hipoglucemiantes/efectos adversos , Insulina , Insulina de Acción Prolongada , Metaanálisis en Red
4.
Environ Toxicol ; 35(7): 783-793, 2020 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-32096903

RESUMEN

The primary metabolize of chlorpyrifos (CPF) is in the liver tissue, which it can cause oxidative damage and apoptosis in liver cells. The use of exercise with antioxidant supplements could have a protective effects in the liver tissue especially by improve mitochondria function. The aim of the present study was to investigate the protective effect of aerobic exercise and eugenol (Eu) supplementation on destructive effects of CPF in liver tissue. Sixty-four adult male albino rats were randomly divided into eight groups (eight rats in each group). Four experimental groups received intraperitoneal injection of either 3.0 mg/kg body weight CPF in dimethyl sulfoxide for six consecutive weeks. Aerobic exercise was performed 5 days per week over 4 weeks for exercise groups. Finally, the animals were sacrificed for the histomorphometric analysis and biochemical measurement in the liver tissue. The result of this study show that consumption of CPF alone, caused collagen deposition, increased apoptosis, tumor necrosis factor α, malondialdehyde, and decreased catalase, superoxide dismutase, acetylcholinesterase (AChE) compared to control and exercise groups (healthy groups) in liver tissue (P ˂ .05). Prescription of exercises and Eu supplements in CPF consumer groups, neutralized this destructive effects of CPF. However, concomitant administration of Eu with exercise had better effects on liver tissue (P ˂ .05). It seems that consumption of Eu with aerobic exercise have a protective role in tissue destruction, inflammatory damage by improving antioxidant defense and modulating AChE activity in hepatocytes.


Asunto(s)
Acetilcolinesterasa/metabolismo , Antioxidantes/metabolismo , Cloropirifos/toxicidad , Eugenol/farmacología , Hígado/efectos de los fármacos , Condicionamiento Físico Animal , Animales , Catalasa/metabolismo , Enfermedad Hepática Inducida por Sustancias y Drogas/metabolismo , Enfermedad Hepática Inducida por Sustancias y Drogas/prevención & control , Suplementos Dietéticos , Hígado/enzimología , Masculino , Malondialdehído/metabolismo , Estrés Oxidativo/efectos de los fármacos , Distribución Aleatoria , Ratas , Ratas Wistar , Superóxido Dismutasa/metabolismo
5.
Nature ; 549(7670): 23-25, 2017 09 06.
Artículo en Inglés | MEDLINE | ID: mdl-28880300
6.
Pharmacoepidemiol Drug Saf ; 27(6): 557-566, 2018 06.
Artículo en Inglés | MEDLINE | ID: mdl-29573031

RESUMEN

PURPOSE: Tuberculosis (TB) remains a common cause of death globally. A regimen of 12 doses of isoniazid (INH) and rifapentine given once weekly (INH/RPT-3) has recently been recommended by the World Health Organization for the treatment of latent TB infection (LTBI). We aimed to determine whether the INH/RPT-3 regimen had similar or lesser rates of adverse events compared to other LTBI regimens, namely INH for 9 months, INH for 6 months, rifampin for 3 to 4 months, and rifampin plus INH for 3 to 4 months. METHODS: We searched MEDLINE, Embase, CENTRAL, PubMed, ICTRP, clinicaltrials.gov, and Canadian Agency for Drugs and Technologies in Health's Gray Matters Light for randomized, postmarketing, and comparative nonrandomized studies of patients with confirmed LTBI that reported the frequency of at least 1 adverse event of relevance for a regimen of interest. The search included studies published until March 2017. The frequencies of adverse events were extracted and are presented descriptively. RESULTS: Data from 23 randomized and 55 nonrandomized studies were included. Although inconsistent event reporting and high heterogeneity limited comparisons, the adverse event profile of INH/RPT-3 appeared generally favorable. Flu-like reactions were reported with an increased frequency and hepatotoxicity with a lower frequency than standard treatment. CONCLUSIONS: While INH/RPT-3 had an overall low frequency of adverse events compared to INH monotherapy, reporting of adverse events for many regimens was limited meaning results should be interpreted cautiously. Future studies of LTBI treatment would benefit from more complete collection and reporting of adverse events and more consistent definitions of hepatotoxicity.


Asunto(s)
Antituberculosos/efectos adversos , Enfermedad Hepática Inducida por Sustancias y Drogas/epidemiología , Isoniazida/efectos adversos , Tuberculosis Latente/tratamiento farmacológico , Enfermedades Respiratorias/epidemiología , Rifampin/análogos & derivados , Antituberculosos/administración & dosificación , Enfermedad Hepática Inducida por Sustancias y Drogas/etiología , Ensayos Clínicos como Asunto , Relación Dosis-Respuesta a Droga , Esquema de Medicación , Quimioterapia Combinada/efectos adversos , Quimioterapia Combinada/métodos , Humanos , Incidencia , Isoniazida/administración & dosificación , Enfermedades Respiratorias/inducido químicamente , Rifampin/administración & dosificación , Rifampin/efectos adversos
7.
BMC Med ; 15(1): 95, 2017 05 05.
Artículo en Inglés | MEDLINE | ID: mdl-28472982

RESUMEN

BACKGROUND: Pregnant women with epilepsy frequently experience seizures related to pregnancy complications and are often prescribed anti-epileptic drugs (AEDs) to manage their symptoms. However, less is known about the comparative safety of AED exposure in utero. We aimed to compare the risk of congenital malformations (CMs) and prenatal outcomes of AEDs in infants/children who were exposed to AEDs in utero through a systematic review and Bayesian random-effects network meta-analysis. METHODS: MEDLINE, EMBASE, and Cochrane CENTRAL were searched from inception to December 15, 2015. Two reviewers independently screened titles/abstracts and full-text papers for experimental and observational studies comparing mono- or poly-therapy AEDs versus control (no AED exposure) or other AEDs, then abstracted data and appraised the risk of bias. The primary outcome was incidence of major CMs, overall and by specific type (cardiac malformations, hypospadias, cleft lip and/or palate, club foot, inguinal hernia, and undescended testes). RESULTS: After screening 5305 titles and abstracts, 642 potentially relevant full-text articles, and 17 studies from scanning reference lists, 96 studies were eligible (n = 58,461 patients). Across all major CMs, many AEDs were associated with higher risk compared to control. For major CMs, ethosuximide (OR, 3.04; 95% CrI, 1.23-7.07), valproate (OR, 2.93; 95% CrI, 2.36-3.69), topiramate (OR, 1.90; 95% CrI, 1.17-2.97), phenobarbital (OR, 1.83; 95% CrI, 1.35-2.47), phenytoin (OR, 1.67; 95% CrI, 1.30-2.17), carbamazepine (OR, 1.37; 95% CrI, 1.10-1.71), and 11 polytherapies were significantly more harmful than control, but lamotrigine (OR, 0.96; 95% CrI, 0.72-1.25) and levetiracetam (OR, 0.72; 95% CrI, 0.43-1.16) were not. CONCLUSION: The newer generation AEDs, lamotrigine and levetiracetam, were not associated with significant increased risks of CMs compared to control, and were significantly less likely to be associated with children experiencing cardiac malformations than control. However, this does not mean that these agents are not harmful to infants/children exposed in utero. Counselling is advised concerning teratogenic risks when the prescription is written for a woman of childbearing age and before women continue with these agents when considering pregnancy, such as switching from polytherapy to monotherapy with evidence of lower risk and avoiding AEDs, such as valproate, that are consistently associated with CMs. These decisions must be balanced against the need for seizure control. SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD42014008925.


Asunto(s)
Anomalías Inducidas por Medicamentos , Anticonvulsivantes/efectos adversos , Epilepsia/tratamiento farmacológico , Complicaciones del Embarazo/tratamiento farmacológico , Adulto , Anticonvulsivantes/uso terapéutico , Teorema de Bayes , Niño , Femenino , Humanos , Lactante , Metaanálisis en Red , Embarazo , Resultado del Embarazo , Adulto Joven
8.
BMC Infect Dis ; 17(1): 265, 2017 04 11.
Artículo en Inglés | MEDLINE | ID: mdl-28399802

RESUMEN

BACKGROUND: We conducted a systematic review and network meta-analysis (NMA) to examine the efficacy and completion rates of treatments for latent tuberculosis infection (LTBI). While a previous review found newer, short-duration regimens to be effective, several included studies did not confirm LTBI, and analyses did not account for variable follow-up or assess completion. METHODS: We searched MEDLINE, Embase, CENTRAL, PubMed, and additional sources to identify RCTs in patients with confirmed LTBI that involved a regimen of interest and reported on efficacy or completion. Regimens of interest included isoniazid (INH) with rifapentine once weekly for 12 weeks (INH/RPT-3), 6 and 9 months of daily INH (INH-6; INH-9), 3-4 months daily INH plus rifampicin (INH/RFMP 3-4), and 4 months daily rifampicin alone (RFMP-4). NMAs were performed to compare regimens for both endpoints. RESULTS: Sixteen RCTs (n = 44,149) and 14 RCTs (n = 44,128) were included in analyses of efficacy and completion. Studies were published between 1968 and 2015, and there was diversity in patient age and comorbidities. All regimens of interest except INH-9 showed significant benefits in preventing active TB compared to placebo. Comparisons between active regimens did not reveal significant differences. While definitions of regimen completion varied across studies, regimens of 3-4 months were associated with a greater likelihood of adequate completion. CONCLUSIONS: Most of the active regimens showed an ability to reduce the risk of active TB relative to no treatment, however important differences between active regimens were not found. Shorter rifamycin-based regimens may offer comparable benefits to longer INH regimens. Regimens of 3-4 months duration are more likely to be completed than longer regimens.


Asunto(s)
Antituberculosos/uso terapéutico , Isoniazida/uso terapéutico , Tuberculosis Latente/tratamiento farmacológico , Rifampin/análogos & derivados , Quimioterapia Combinada , Humanos , Masculino , Metaanálisis en Red , Rifampin/uso terapéutico , Factores de Tiempo
9.
Behav Pharmacol ; 27(5): 431-8, 2016 08.
Artículo en Inglés | MEDLINE | ID: mdl-26871404

RESUMEN

Orexins, which are mainly produced by orexin-expressing neurons in the lateral hypothalamus (LH), play an important role in pain modulation. Previously, it has been established that the nucleus accumbens (NAc) is involved in the modulation of formalin-induced nociceptive responses, a model of tonic pain. In this study, the role of intra-accumbal orexin-2 receptors (OX2rs) in the mediation of formalin-induced pain was investigated. A volume of 0.5 µl of 10, 20, and 40 nmol/l solutions of TCS OX2 29, an OX2r antagonist, were unilaterally microinjected into the NAc 5 min before an intra-LH carbachol microinjection (0.5 µl of 250 nmol/l solution). After 5 min, animals received a subcutaneous injection of formalin 2.5% (50 µl) into the hind paw. Pain-related behaviors were assessed at 5 min intervals during a 60-min test period. The findings showed that TCS OX2 29 administration dose dependently blocked carbachol-induced antinociception during both phases of formalin-induced pain. The antianalgesic effect of TCS OX2 29 was greater during the late phase compared with the early phase. These observations suggest that the NAc, as a part of a descending pain-modulatory circuitry, partially mediates LH-induced analgesia in the formalin test through recruitment of OX2rs. This makes the orexinergic system a good potential therapeutic target in the control of persistent inflammatory pain.


Asunto(s)
Carbacol/farmacología , Isoquinolinas/farmacología , Receptores de Orexina/efectos de los fármacos , Dolor/tratamiento farmacológico , Piridinas/farmacología , Analgésicos no Narcóticos/administración & dosificación , Analgésicos no Narcóticos/farmacología , Animales , Modelos Animales de Enfermedad , Relación Dosis-Respuesta a Droga , Área Hipotalámica Lateral/efectos de los fármacos , Área Hipotalámica Lateral/metabolismo , Isoquinolinas/administración & dosificación , Masculino , Microinyecciones , Núcleo Accumbens/efectos de los fármacos , Núcleo Accumbens/metabolismo , Antagonistas de los Receptores de Orexina/administración & dosificación , Antagonistas de los Receptores de Orexina/farmacología , Receptores de Orexina/metabolismo , Orexinas/metabolismo , Dolor/patología , Dimensión del Dolor , Piridinas/administración & dosificación , Ratas , Ratas Wistar
10.
Mol Cell Biochem ; 404(1-2): 97-102, 2015 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-25739358

RESUMEN

In erythrocyte, catalase plays an important role to protect cells from hydrogen peroxide toxicity. Hydrogen peroxide is a byproduct compound which is produced during metabolic pathway of cells. Cimetidine, a histamine H2 receptor antagonist, is used for gastrointestinal tract diseases and prevents the extra release of gastric acid. In this study, the effect of cimetidine on the activity of human erythrocyte catalase was investigated. Erythrocytes were broken by hypotonic solution. The supernatant was used for catalase assay and kinetics study. Lineweaver-Burk plot was performed to determine the type of inhibition. The kinetics data revealed that cimetidine inhibited the catalase activity by mixed inhibition. The IC50 (1.54 µM) and Ki (0.45 µM) values of cimetidine determined that the drug was bound to the enzyme with high affinity. Circular dichroism and fluorescence measurement showed that the binding of cimetidine to the enzyme affected the content of secondary structure of the enzyme as well as its conformational changes. Docking studies were carried out to detect the site in which the drug was bound to the enzyme. Molecular modeling and energy calculation of the binding showed that the cyanoguanidine group of the drug connected to Asp59 via two hydrogen bonds, while the imidazole group of the drug interacted with Phe64 in the enzyme by a hydrophobic interaction. In conclusion, cimetidine could bind to human erythrocyte catalase, and its interaction caused functional and conformational changes in the enzyme.


Asunto(s)
Catalasa/metabolismo , Cimetidina/farmacología , Eritrocitos/enzimología , Relación Estructura-Actividad , Sitios de Unión , Catalasa/química , Eritrocitos/efectos de los fármacos , Humanos , Peróxido de Hidrógeno/metabolismo , Cinética , Modelos Moleculares , Simulación del Acoplamiento Molecular , Unión Proteica/efectos de los fármacos , Conformación Proteica/efectos de los fármacos
11.
Carbohydr Polym ; 320: 121230, 2023 Nov 15.
Artículo en Inglés | MEDLINE | ID: mdl-37659817

RESUMEN

Chitosan is a modified natural carbohydrate polymer that has been found in the exoskeletons of crustaceans (e.g., lobsters, shrimps, krill, barnacles, crayfish, etc.), mollusks (octopus, oysters, squids, snails), algae (diatoms, brown algae, green algae), insects (silkworms, beetles, scorpions), and the cell walls of fungi (such as Ascomycetes, Basidiomycetes, and Phycomycetes; for example, Aspergillus niger and Penicillium notatum). However, it is mostly acquired from marine crustaceans such as shrimp shells. Chitosan-based composites often present superior chemical, physical, and mechanical properties compared to single chitosan by incorporating the benefits of both counterparts in the nanocomposites. The tunable surface chemistry, abundant surface-active sites, facilitation synthesize and functionalization, good recyclability, and economic viability make the chitosan-based materials potential adsorbents for effective and fast removal of a broad range of inorganic anions. This article reviews the different types of inorganic anions and their effects on the environment and human health. The development of the chitosan-based composites synthesis, the various parameters like initial concentration, pH, adsorbent dosage, temperature, the mechanism of adsorption, and regeneration of adsorbents are discussed in detail. Finally, the prospects and technical challenges are emphasized to improve the performance of chitosan-based composites in actual applications on a pilot or industrial scale.

12.
Int J Biol Macromol ; 240: 124159, 2023 Jun 15.
Artículo en Inglés | MEDLINE | ID: mdl-37003394

RESUMEN

Developing a facile and green strategy to fabricate polymer foams with super hydrophobicity and eco-friendliness for large-scale oil-water separation remains a challenge. In this study, biocompatible polylactic acid polymer foam modified by nanochitosan and stearic acid was used to remove petroleum and organic contaminants in water. All three materials used to prepare and modify this foam are green and inexpensive. F4d foam (prepared by solvent displacement method) and F8d foam (prepared by freeze dryer) can selectively remove oil pollutants in water with a contact angle of 164.01° and 168.51°, respectively. The maximum absorption capacity of oil pollutants by F4d and F8d are related to chloroform with values of 32.7 g/g and 48.51 g/g, respectively. Also, the minimum absorption capacity is related to n-hexane with values of 24.83 g/g and 32.06 g/g. The absorption percentage range of F4d and F8d foams after 15 cycles of absorption-desorption for chloroform is 82.56 % and 87.81 %, respectively, and for n-hexane, is 77.28 % and 85.99 %, respectively. During the continuous water-oil pumping test, the efficiency of foam can be maintained for >15 h, which shows promising hope for large-scale oil pollution cleaning.


Asunto(s)
Contaminantes Ambientales , Agua , Cloroformo , Polímeros
13.
Chemosphere ; 332: 138852, 2023 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-37146776

RESUMEN

CdS/ZnO nanosheets heterostructures ((x)CdS/ZNs) with different mole ratios of Cd/Zn ((x) = 0.2, 0.4, and 0.6) were synthesized by the impregnation-calcination method. PXRD patterns showed that the (100) diffraction of ZNs was the most significant in the (x)CdS/ZNs heterostructures, and it confirmed that CdS nanoparticles (in cubic phase) occupied the (101) and (002) crystal facets of ZNs with hexagonal wurtzite crystal phase. UV-Vis DRS results indicated that CdS nanoparticles decreased the band gap energy of ZNs (2.80-2.11 eV) and extended the photoactivity of ZNs to the visible light region. The vibrations of ZNs were not observed clearly in the Raman spectra of (x)CdS/ZNs due to the extensive coverage of CdS nanoparticles shielding the deeper-laying ZNs from Raman response. The photocurrent of (0.4) CdS/ZNs photoelectrode reached 33 µA, about 82 times higher than that for ZNs (0.4 µA, 0.1 V vs Ag/AgCl). The formation of an n-n junction at the (0.4) CdS/ZNs reduced the recombination of electron-hole pairs and increased the degradation performance of the as-prepared (0.4) CdS/ZNs heterostructure. The highest percentage removal of tetracycline (TC) in the sonophotocatalytic/photocatalytic processes was obtained by (0.4) CdS/ZNs under visible light. The quenching tests showed that O2•-, h+, and OH• were the main active species in the degradation process. The degradation percentage decreased negligibly in the sonophotocatalytic (84%-79%) compared to the photocatalytic (90%-72%) process after four re-using runs due to the presence of ultrasonic waves. For the estimation of degradation behavior, two machine learning methods were applied. The comparison between the ANN and GBRT models evidenced that both models had high prediction accuracy and could be used for predicting and fitting the experimental data of the %removal of TC. The excellent sonophotocatalytic/photocatalytic performance and stability of the fabricated (x)CdS/ZNs catalysts made them promising candidates for wastewater purification.


Asunto(s)
Compuestos Heterocíclicos , Óxido de Zinc , Óxido de Zinc/química , Luz , Tetraciclina , Compuestos de Zinc/química , Antibacterianos/química
14.
BMJ Open ; 13(2): e067771, 2023 02 15.
Artículo en Inglés | MEDLINE | ID: mdl-36792322

RESUMEN

OBJECTIVES: To chart the global literature on gender equity in academic health research. DESIGN: Scoping review. PARTICIPANTS: Quantitative studies were eligible if they examined gender equity within academic institutions including health researchers. PRIMARY AND SECONDARY OUTCOME MEASURES: Outcomes related to equity across gender and other social identities in academia: (1) faculty workforce: representation of all genders in university/faculty departments, academic rank or position and salary; (2) service: teaching obligations and administrative/non-teaching activities; (3) recruitment and hiring data: number of applicants by gender, interviews and new hires for various rank; (4) promotion: opportunities for promotion and time to progress through academic ranks; (5) academic leadership: type of leadership positions, opportunities for leadership promotion or training, opportunities to supervise/mentor and support for leadership bids; (6) scholarly output or productivity: number/type of publications and presentations, position of authorship, number/value of grants or awards and intellectual property ownership; (7) contextual factors of universities; (8) infrastructure; (9) knowledge and technology translation activities; (10) availability of maternity/paternity/parental/family leave; (11) collaboration activities/opportunities for collaboration; (12) qualitative considerations: perceptions around promotion, finances and support. RESULTS: Literature search yielded 94 798 citations; 4753 full-text articles were screened, and 562 studies were included. Most studies originated from North America (462/562, 82.2%). Few studies (27/562, 4.8%) reported race and fewer reported sex/gender (which were used interchangeably in most studies) other than male/female (11/562, 2.0%). Only one study provided data on religion. No other PROGRESS-PLUS variables were reported. A total of 2996 outcomes were reported, with most studies examining academic output (371/562, 66.0%). CONCLUSIONS: Reviewed literature suggest a lack in analytic approaches that consider genders beyond the binary categories of man and woman, additional social identities (race, religion, social capital and disability) and an intersectionality lens examining the interconnection of multiple social identities in understanding discrimination and disadvantage. All of these are necessary to tailor strategies that promote gender equity. TRIAL REGISTRATION NUMBER: Open Science Framework: https://osf.io/8wk7e/.


Asunto(s)
Docentes , Equidad de Género , Embarazo , Humanos , Masculino , Femenino , Liderazgo , Salarios y Beneficios , Recursos Humanos , Docentes Médicos
15.
Artículo en Inglés | MEDLINE | ID: mdl-22203884

RESUMEN

Background. Back pain is a common problem and a major cause of disability and health care utilization. Purpose. To evaluate the efficacy, harms, and costs of the most common CAM treatments (acupuncture, massage, spinal manipulation, and mobilization) for neck/low-back pain. Data Sources. Records without language restriction from various databases up to February 2010. Data Extraction. The efficacy outcomes of interest were pain intensity and disability. Data Synthesis. Reports of 147 randomized trials and 5 nonrandomized studies were included. CAM treatments were more effective in reducing pain and disability compared to no treatment, physical therapy (exercise and/or electrotherapy) or usual care immediately or at short-term follow-up. Trials that applied sham-acupuncture tended towards statistically nonsignificant results. In several studies, acupuncture caused bleeding on the site of application, and manipulation and massage caused pain episodes of mild and transient nature. Conclusions. CAM treatments were significantly more efficacious than no treatment, placebo, physical therapy, or usual care in reducing pain immediately or at short-term after treatment. CAM therapies did not significantly reduce disability compared to sham. None of the CAM treatments was shown systematically as superior to one another. More efforts are needed to improve the conduct and reporting of studies of CAM treatments.

16.
Endocrinol Diabetes Metab ; 5(6): e387, 2022 11.
Artículo en Inglés | MEDLINE | ID: mdl-36266776

RESUMEN

INTRODUCTION: Cardiovascular diseases are very common in the general population, and several factors play a role in their development. The purpose of this study was to investigate the relationship between hyperuricaemia and other cardiovascular disease risk factors. METHODS: This cross-sectional study was conducted on 1008 people over the 15-year-old general population in Kerman, Iran. The blood samples of all patients were analysed for the uric acid serum level, and they completed a checklist including physical activity, previous history of hypertension and diabetes, smoking and opium. RESULTS: A number of 1008 cases of people were entered into the study. According to the results of this study, 254 patients had uric acid levels above the 75th percentile (6 mg/dl in males, and 5 mg/dl in females). No significant difference was observed between gender (p = .249) and age groups (p = .125) of people with and without hyperuricaemia. The prevalence of overweight/obesity (p < .001), hypertension (p = .004) and low physical activity (p = .033) was significantly higher in patients with hyperuricaemia. The duration of hypertension was significantly higher in hyperuricaemic individuals (p = .022). Overweight/obesity (OR = 2.67; 95% CI = 1.87-3.82) and hypertension (OR = 1.40; 95% CI = 1.02-1.93) were two significant independent factors that contributed to the increased risk of hyperuricaemia in the subjects. CONCLUSION: The uric acid serum level is higher in people with hypertension and overweight/obesity. Hyperuricaemia increases the risk of cardiovascular events, which can be prevented by determining the appropriate strategy for the early diagnosis and treatment of this metabolic disorder.


Asunto(s)
Enfermedades Cardiovasculares , Hipertensión , Hiperuricemia , Masculino , Femenino , Humanos , Adolescente , Hiperuricemia/complicaciones , Hiperuricemia/epidemiología , Hiperuricemia/diagnóstico , Ácido Úrico/metabolismo , Enfermedades Cardiovasculares/epidemiología , Enfermedades Cardiovasculares/etiología , Estudios Transversales , Sobrepeso/complicaciones , Factores de Riesgo , Hipertensión/epidemiología , Hipertensión/etiología , Obesidad/complicaciones
17.
Iran J Public Health ; 51(6): 1223-1231, 2022 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-36447978

RESUMEN

Background: Irritable bowel syndrome (IBS) is a highly prevalent disorder of the gut interaction characterized by abdominal discomfort and pain associated with altered bowel habits in the absence of structural abnormalities. In spite of IBS' high prevalence and disease burden across the globe, no explanations have been given as to its underlying pathophysiology. As for the treatment of IBS, there is no specific medication, and the most beneficial treatment is usually supportive therapy. Recent animal and human studies have demonstrated the therapeutic potential of curcumin or turmeric in the treatment of IBS. Methods: We systematically reviewed all available evidence supporting curcumin and turmeric's therapeutic potential in relieving IBS symptoms in the present study. For this purpose, a database search was performed using curcumin, turmeric, and IBS and all their equivalents as of the search terms in Web of Science, Pub-Med, Scopus, Ovid, Embase, and Google Scholar from1990 up to Feb 2021. The investigation was then limited to clinical trials, and then nine articles were collected for data analysis. Results: The findings of the included literature showed that curcumin and turmeric alone or in combination with other medications could improve the severity of IBS as well as the quality of life among people who suffer from IBS symptoms. Conclusion: Overall, medications containing curcumin and turmeric extract due to these compounds' anti-inflammatory effects may improve IBS symptoms, particularly abdominal pain and life quality.

18.
BMJ Open ; 12(6): e045115, 2022 06 03.
Artículo en Inglés | MEDLINE | ID: mdl-35947494

RESUMEN

OBJECTIVES: The COVID-19 pandemic has stimulated growing research on treatment options. We aim to provide an overview of the characteristics of studies evaluating COVID-19 treatment. DESIGN: Rapid scoping review DATA SOURCES: Medline, Embase and biorxiv/medrxiv from inception to 15 May 2021. SETTING: Hospital and community care. PARTICIPANTS: COVID-19 patients of all ages. INTERVENTIONS: COVID-19 treatment. RESULTS: The literature search identified 616 relevant primary studies of which 188 were randomised controlled trials and 299 relevant evidence syntheses. The studies and evidence syntheses were conducted in 51 and 39 countries, respectively.Most studies enrolled patients admitted to acute care hospitals (84%), included on average 169 participants, with an average age of 60 years, study duration of 28 days, number of effect outcomes of four and number of harm outcomes of one. The most common primary outcome was death (32%).The included studies evaluated 214 treatment options. The most common treatments were tocilizumab (11%), hydroxychloroquine (9%) and convalescent plasma (7%). The most common therapeutic categories were non-steroidal immunosuppressants (18%), steroids (15%) and antivirals (14%). The most common therapeutic categories involving multiple drugs were antimalarials/antibiotics (16%), steroids/non-steroidal immunosuppressants (9%) and antimalarials/antivirals/antivirals (7%). The most common treatments evaluated in systematic reviews were hydroxychloroquine (11%), remdesivir (8%), tocilizumab (7%) and steroids (7%).The evaluated treatment was in favour 50% and 36% of the evaluations, according to the conclusion of the authors of primary studies and evidence syntheses, respectively. CONCLUSIONS: This rapid scoping review characterised a growing body of comparative-effectiveness primary studies and evidence syntheses. The results suggest future studies should focus on children, elderly ≥65 years of age, patients with mild symptoms, outpatient treatment, multimechanism therapies, harms and active comparators. The results also suggest that future living evidence synthesis and network meta-analysis would provide additional information for decision-makers on managing COVID-19.


Asunto(s)
Antimaláricos , Tratamiento Farmacológico de COVID-19 , COVID-19 , Anciano , Antivirales/uso terapéutico , COVID-19/terapia , Niño , Humanos , Hidroxicloroquina/uso terapéutico , Inmunización Pasiva , Inmunosupresores , Persona de Mediana Edad , Pandemias , Ensayos Clínicos Controlados Aleatorios como Asunto , Sueroterapia para COVID-19
19.
Daru ; 29(1): 159-170, 2021 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-33880740

RESUMEN

BACKGROUND: Polychlorinated biphenyls (PCBs) are a group of synthetic organic chlorine compounds known as an organic pollutant in food sources, which play important roles in malignancies. The present study aimed to investigate the direct effects of prevalent PCBs in food in hormone-responsive and non-responsive cell lines. METHODS: In the current study, MCF-7, LNCap, and MDA-MB231 cell lines were treated with serial concentrations (0.001-100 µM) of PCBs for 48 h and cell viability assessment was performed using MTT assay. The best concentration then applied and the expression level of PON1 was evaluated using real-time PCR. Besides, molecular docking was performed to determine the binding mechanism and predicted binding energies of PBCs compounds to the AhR receptor. RESULTS: Unlike MCF-7 and LNCap cells, the viability of MDA-MB231 cells did not significantly change by different concentrations of PCBs. Meanwhile, quantitative gene expression analysis showed that the PON1 was significantly more expressed in MCF-7 and LNCap lines treated with PCB28 and PCB101. However, the expression level of this gene in other groups and also MDA-MB231cells did not demonstrate any significantly change. Also, the results of molecular docking showed that PBCs had steric interaction with AhR receptor. CONCLUSIONS: Current results showed that despite of hormone non-responsive cells the PCBs have a significant positive effect on hormone-responsive cell. Therefore, and regarding to the existence of PCBs contamination in food there should be serious concern about their impact on the prevalence of different malignancies which certainly should result in a standard limit for this material. This study aimed to investigate the direct effects of prevalent PCBs in food in hormone-responsive and non-responsive cell lines. Cell lines were treated with serial concentrations of PCBs and cell viability assessment was performed using MTT assay. The expression level of PON1 was evaluated using real-time PCR. Molecular docking was performed to determine the binding mechanism and predicted binding energies of PBCs compounds to the AhR receptor. PCBs contamination in food there should be serious concern about their impact on the prevalence of different malignancies which certainly should result in a standard limit for this material.


Asunto(s)
Contaminantes Ambientales/farmacología , Contaminación de Alimentos , Bifenilos Policlorados/farmacología , Arildialquilfosfatasa/genética , Línea Celular Tumoral , Proliferación Celular/efectos de los fármacos , Supervivencia Celular/efectos de los fármacos , Expresión Génica/efectos de los fármacos , Humanos , Simulación del Acoplamiento Molecular , Unión Proteica , Receptores de Hidrocarburo de Aril/metabolismo
20.
J Psychiatr Res ; 141: 192-198, 2021 09.
Artículo en Inglés | MEDLINE | ID: mdl-34242926

RESUMEN

BACKGROUND AND OBJECTIVES: Obsessive-compulsive disorder (OCD) is a disease that causes personal distress or social dysfunction, especially in childhood. The present study aimed to provide the prevalence, comorbidity, and predictors of OCD among children and adolescents. METHODS: This was a cross-sectional national project conducted on 29,858 children and adolescents using the multi-stage cluster random sampling in Iran. There were both genders in each cluster and three age groups (6-9, 10-14, and 15-18 years) within each cluster. The tools used in this research included a demographic questionnaire and K-SADS-PL. To analyze the data, logistic regression and cross-tab tests were used. RESULTS: According to the results, the prevalence of OCD in children and adolescents was 3.1 in boys and 3.8 in girls. Also, gender, age, place of residence, and history of psychiatric hospitalization of parents could predict OCD. OCD had comorbidity with behavioral disorders (OR = 0.60, 95%CI: 0.39-0.92), elimination disorders (OR = 0.50, 95%CI: 0.30-0.83), mood disorders (OR = 2.92, 95%CI: 1.43-5.94), and smoking and alcohol disorders (OR = 4.33, 95%CI: 1.28-14.63). CONCLUSION: In the development of the obsessive-compulsive disorder, other disorders and symptoms also environmental factors can play a role and are important. Based on our findings, given the prevalence rate of OCD was higher in the age groups of 10-14 and 15-18 years, are one of the most important stages of development for the prevention and treatment of mental disorders, especially OCD, clinical specialists can design appropriate clinical trials or modify existing interventions based on the results of such research.


Asunto(s)
Trastorno Obsesivo Compulsivo , Adolescente , Niño , Comorbilidad , Estudios Transversales , Femenino , Humanos , Irán/epidemiología , Masculino , Trastorno Obsesivo Compulsivo/epidemiología , Prevalencia
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA